linjc16/ctgov huggingface dataset:
A Polymerase Chain Reaction (PCR) - Based Method to Improve Antibiotic Prescribing for Pneumonia

Study Overview
=================
Brief Summary
-----------------
Pneumonia, or lung infection, is usually treated with antibiotics targeted against the organisms that the physician guesses are causing the problem. The determination of the exact cause of a patient's pneumonia is difficult. The problem is that the two major causes of community-acquired pneumonia are not easily distinguished on clinical grounds and are best treated by different antibiotics. The investigators hypothesize that antibiotic therapy can be targeted and improved by doing polymerase chain reaction (PCR) testing of nose swabs to identify probable implicated organisms and their antibiotic resistance patterns. This pilot study will be important to ensure that the laboratory testing is functional and that the emergency department-laboratory communication is optimal prior to doing a full-fledged randomized clinical trial.

Official Title
-----------------
A Polymerase Chain Reaction-based Method to Improve Antibiotic Prescribing for Children and Adolescents With Community-Acquired Pneumonia - a Pilot Study

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Procedure: nasopharyngeal swab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presumed community-acquired pneumonia as diagnosed by the attending emergency department physician Exclusion Criteria: age > 6 months immunodeficiency (primary, advanced HIV) cystic fibrosis malignancy known cardiac or lung defects bronchiectasis previous pneumonia or lung abscess in past 6 months conditions requiring treatment with immune suppressants

Ages Eligible for Study
-----------------
Minimum Age: 180 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pneumonia<br>Children diagnosed with community-acquired pneumonia by the emergency department physician | Procedure: nasopharyngeal swab<br>* PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pneumonia, community-acquired, polymerase chain reaction, pneumococcus, mycoplasma, chlamydophila, anti-bacterial agents
Long Term Survivors in Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
In this study the investigators would like to explore the patient and tumour characteristics of long-term survivors of ovarian cancer (>10 years). Indentifiying the characteristics of long-term survivors not only helps find prognostic factors for survival but may aid in generating hypotheses for novel therapeutic strategies.

Official Title
-----------------
Long Term Survivors in Ovarian Cancer

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Other: Retrospective, cross-sectional descriptive analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To achieve a large enough study population of approximately 80 subjects, patients surviving >10 years after treatment for stage IIIC/IV epithelial ovarian cancer in the past 25 years will be included from five hospitals. Patients were diagnosed between 1979 and 2006 and treated in the north of the Netherlands. A list of subjects fitting these inclusion criteria will be extracted from the National Cancer Registry (NKR).
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| long-term survivors of ovarian cancer<br>long-term survivors of ovarian cancer | Other: Retrospective, cross-sectional descriptive analysis<br>* This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Indentifiying the characteristics of long-term survivors | Indentifiying the characteristics of long-term survivors | 2 years |
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to assess the proportion of schizophrenic patients and the proportion of bipolar patients who discontinue olanzapine within 12 months of treatment in outpatient, ambulatory or community settings

Official Title
-----------------
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.

Conditions
-----------------
Schizophrenia, Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: olanzapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients suffering from schizophrenic or schizoaffective disorders based on the disease diagnostic criteria DSM IV and being prescribed olanzapine during the 45 preceding days. patients suffering from bipolar disorders based on the disease diagnostic criteria DSM IV and being prescribed olanzapine during the 45 preceding days for one of the following: moderate or severe manic episode relapse prevention in patients with bipolar disorder Exclusion Criteria: current treatment with any investigational drug or procedure at entry or during the whole study hypersensitivity to olanzapine patients with known narrow angle glaucoma risk

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| olanzapine coated tablet<br> | Drug: olanzapine<br> <br> |
| olanzapine orodispersable tablet<br> | Drug: olanzapine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Subgroup of Patients on Oral Anticoagulants

Study Overview
=================
Brief Summary
-----------------
To investigate whether omitting systemic anticoagulation during transradial coronary angiography and/or a distal radial access reduce the risk of postprocedural radial artery occlusion

Official Title
-----------------
Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Subgroup of Patients on Oral Anticoagulants

Conditions
-----------------
Patient Undergoing Diagnostic Coronary Angiography

Intervention / Treatment
-----------------
* Other: Distal radial access
* Other: Distal radial access


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical indication to perform diagnostic coronary angiography Pretreatment with oral anticoagulants (phenprocoumon or direct oral anticoagulants [dabigatran, apixaban, rivaroxaban, or edoxaban]) Age > 18 years Written informed consent Exclusion Criteria: Already administered additional anticoagulation prior to coronary angiography Planned coronary intervention Preexisting radial artery occlusion or missing pulse at the potential puncture sites Allergy / intolerance to anticoagulants Active bleeding or comorbidity with elevated bleeding risk Pregnancy Inability to sign informed consent Participation in another trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group-1<br>No anticoagulation | Other: Distal radial access<br>* Distal radial access and No anticoagulation<br>|
| Active Comparator: Group-2<br>ACT-guided anticoagulation | Other: Distal radial access<br>* Distal radial access and ACT-guided anticoagulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of postprocedural radial artery occlusion | Will be the occurrence of postprocedural radial artery occlusion assessed with high-resolution vascular ultrasound. Experienced sonographers will perform color Doppler ultrasound in all study patients after removal of the compression device to examine the radial, ulnar, and brachial arteries of the access forearm. | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sonographic characteristics of radial artery occlusion | Occlusion lengths or minimal residual perfusion | 3 Month |
Oxycodone Pharmacokinetics in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
The pharmacokinetics of oxycodone is well characterized in children older than six months of age. However, only one study has been published with children younger than six months, concluding that unexplained inter-individual variability is pronounced in the youngest children. The aim of the current study was to quantify oxycodone pharmacokinetics in children ranging from preterm newborn infants to children up to two years of age.

Official Title
-----------------
Oxycodone Pharmacokinetics in Preterms, Infants and Children

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Oxycodone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants scheduled for surgery with planned perioperative or postoperative opioid analgesia were screened if the gestational age (GA) was at least 23 weeks and postnatal age (PNA) below 2 years Exclusion Criteria: He/she had allergy or hypersensitivity to oxycodone or other ingredients in the formulations or had received monoamineoxidase, CYP3A (cytochrome P450 3A enzymes) or CYP2D6 (cytochrome P450 2D6 enzyme) inhibitors during the previous month or other reason that was considered to contraindicate participation.

Ages Eligible for Study
-----------------
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Oxycodone<br>Oxycodone 0,1 mg/kg iv | Drug: Oxycodone<br>* oxycodone 0,1 mg/kg iv<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak plasma concentration of oxycodone |  | time zero hours to 24 hours |
Anatomical Study of the Arteries of the Skin on Amputation Legs

Study Overview
=================
Brief Summary
-----------------
PRIMARY OBJECTIVE Qualitatively describe the distribution of cutaneous arteries in patients with long-term occlusive arterial disease. SECONDARY OBJECTIVE To compare the distribution of cutaneous arteries observed on the legs of arteritic patients with that observed on non-arteritic legs (from bodies given to science).

Detailed Description
-----------------
Arterial patient coming to CHRU Nancy, in the Vascular and Endoluminal Surgery Department, to undergo leg amputation. Usually, after the amputation of the leg in the operating theatre, the surgical waste is destroyed. Instead of being destroyed, the leg will be used for research.

Official Title
-----------------
Anatomical Study of the Arteries of the Skin on Amputation Legs

Conditions
-----------------
Arteritic Leg Ulcer

Intervention / Treatment
-----------------
* Biological: artericitc surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major Patient Patient with late stage occlusive arteriopathy with lower limb amputation Patient who did not oppose the search Patient affiliated to a social security scheme Exclusion Criteria: Patients with infectious diseases not accessible in the anatomy laboratory Woman of childbearing age without effective contraception Persons referred to in Articles L. 1121-5 to L. 1121-8 and L1122-2 of the Public Health Code : Pregnant woman, parturient or nursing mother Person deprived of liberty by a judicial or administrative decision, Person under psychiatric care pursuant to Articles L.3212-1 and L.3213-1 of the Public Health Code Person admitted to a health or social institution for purposes other than research Minor person (not emancipated) Adult subject to a legal protection measure (guardianship, trusteeship, protection of justice) Major person who is not in a position to express consent and who is not subject to a legal protection measure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: artericitc surgery|biological sample (leg) from leg amputation surgery used for research|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative mapping of the skin's arteries. | The leg will be transported in a container to the Anatomy Laboratory (Faculty of Medicine - University of Lorraine). Within 72 hours of its arrival, the operating room will be dissected to qualitatively describe the distribution of cutaneous arteries in patients with long-term occlusive arterial disease. | 72 hours after the dissection of the leg. |
Influence of a Single Dose Dexamethasone on the Time Course of Neuromuscular Blockade of Rocuronium

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to compare the time course of a neuromuscular block in patients receiving dexamethasone 8 mg in order to reduce postoperative nausea or vomiting several hours before surgery with patients receiving the drug immediately before induction of anaesthesia and patients without a dexamethasone prophylaxis. The primary end point is the time from start of injection of rocuronium until recovery to a train of four ratio (TOF ratio) of 0.9.

Conditions
-----------------
Neuromuscular Block, Dexamethasone, Neuromuscular Block, Recovery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged 18 to 65 years, American Society of Anesthesiologists Physical Status I or II, 50-90 kg body weight, undergoing elective laparoscopic gynaecological surgery in general anaesthesia necessitating intraoperative neuromuscular blockade. Exclusion Criteria: expected difficulties with endotracheal intubation (history of difficult intubation, reduced opening of the mouth (< 2cm), and Mallampati Score of 4), increased risk of pulmonary aspiration (gastrooesophageal reflux, full stomach, intestinal obstruction), known allergies to the drugs tested, pregnancy, neuromuscular disorders, intake of drugs affecting neuromuscular blockade, such as furosemide, magnesium or cephalosporins, hepatic-or renal insufficiency.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| dexamethasone late<br>dexamethasone during induction of anesthesia | |
| no dexamethasone<br>no dexamethasone during measurements | |
| dexamethasone early<br>dexamethasone before induction of anesthesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the time from start of injection of rocuronium until recovery to a train of four ratio (TOF ratio) of 0.9. |  | one hour |
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This study will assess how radiation affects the patterns of circulating tumor deoxyribonucleic acid (ctDNA) and immune cells (T cells) during radiation treatment in patients with breast cancer. By better understanding how radiation therapy affects these markers (characteristic that is measured to see how well the body responds to a treatment for a disease) in the blood, researchers may better customize treatments for patients with breast cancer in the future.

Official Title
-----------------
Circulating Tumor DNA (ctDNA) and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Histologically confirmed primary or recurrent non-metastatic invasive breast cancer with plans for adjuvant post-lumpectomy or post-mastectomy radiation therapy at the Mayo Clinic and indications for regional nodal irradiation. Or patients undergoing curative intent irradiation for oligometastatic breast cancer (=< 3 sites of metastases) is permitted Willingness to provide informed consent and expresses understanding of this protocol and its requirements, risks, and discomforts Patients with non-metastatic breast cancer must have completed their final breast surgery including re-excision of margins for invasive cancer and ductal carcinoma in situ (DCIS) or chemotherapy within 90 days prior to registration but no sooner than 21 days prior to the initiation of radiation therapy (RT). Bilateral breast cancer is permitted Positive or close margins is allowed Exclusion Criteria: Other active malignancy =< 2 years prior to registration (exceptions: non-melanotic skin cancer or carcinoma-in-situ of the cervix) Pregnancy or lactation Inability on the part of the patient to understand the informed consent to be compliant with the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in the ctDNA detection rate in mutational load in breast cancer patients with indications of regional nodal irradiation. |  | 3 Months | 
| The change in the proportion of patients with detectable ctDNA at the end of treatment and 3 months compared to baseline. |  | 3 Months | 
| The correlation of detectible ctDNA at each time point with invasive recurrence-free survival |  | 3 Months |
VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis

Study Overview
=================
Brief Summary
-----------------
To evaluate additional cardiovascular risk factors using data from the VA HDL Intervention Trial (VA-HIT).

Detailed Description
-----------------
BACKGROUND: The VA HDL Intervention trial (VA-HIT) was a multicenter, placebo controlled, randomized trial that showed that gemfibrozil significantly reduced major cardiovascular events in 2531 men with coronary heart disease, low levels of low density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol. In addition to its unique lipid profile, the VA-HIT population also had a high prevalence of diabetes, impaired fasting glucose, or high fasting plasma insulin; central obesity; and hypertension, which are all components (together with high triglycerides and low HDL-cholesterol) of a constellation of risk factors known as the metabolic syndrome. Since prior clinical trials have not enrolled this type of population, the VA- HIT database is a unique resource. DESIGN NARRATIVE: The study used the VA-HIT database to study additional risk markers that were measured in the study population of 2,531 men with coronary heart disease. Specific analyses were: 1) the association between levels of glucose tolerance, insulin resistance and other features of the metabolic syndrome, occurrence of major cardiovascular outcomes, and gemfibrozil efficacy; 2) the effect of gemfibrozil on progression of carotid atherosclerosis, as measured by B-mode ultrasound; 3) the association between LDL particle size distribution and lipoprotein subclass distribution; homocysteine; lipoprotein(a); C-reactive protein, tissue plasminogen activator; fibrinogen; and factor VII; major cardiovascular outcomes and gemfibrozil efficacy. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Obesity, Coronary Disease, Heart Diseases, Cardiovascular Diseases, Carotid Artery Diseases, Diabetes Mellitus, Non-insulin Dependent, Hypertension, Insulin Resistance, Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |